Government ❯ Health and Human Services ❯ FDA

Drug Safety

Mifepristone Review Mifepristone Regulatory Oversight

Hawley Pressures FDA Chief as Anti‑Abortion Groups Demand Firing Over Reported Mifepristone Review Delay

The FDA describes an evidence‑driven study now in a data‑gathering phase with no projected timeline.